UC San Diego study finds GLP-1 drugs like Ozempic cut colon cancer death rates by more than half within five years; 6,800 patients analyzed across California, strongest effect seen in obese patients due to reduced inflammation and improved metabolism.

GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients

A new University of California San Diego study offers compelling evidence that GLP-1 receptor agonists — the class of drugs behind Ozempic, Wegovy and Mounjaro, for example — may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to those who weren’t on t...